Clinical trials: Gastric Cancer Stage III
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastro-Oesophageal Cancer
RegoNivo vs Standard of Care Chemotherapy in AGOC
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.
- Trial name
- INTEGRATEIIb (NCT04879368)
- Testing
- Regorafenib, Nivolumab, Docetaxel
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 462 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal…
- Trial name
- NCT03221426
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 171 sites in United States, Belgium and 22 more
- Volunteers
- 1,007 people
- Sponsor
- Merck Sharp & Dohme LLC
Gastric Adenocarcinoma, Gastric Cancer
Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Background: Three-fourths of people diagnosed with gastric cancer will die from it. Researchers want to see if giving cancer drugs in a new way can help people live longer and delay the time it takes for the cancer to grow.
- Conditions
- Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
- Trial name
- NCT04034251
- Testing
- Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Gastric Cancer
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
- Trial name
- GRANITE-1 (NCT00879333)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 656 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
This randomized phase II trial studies how well giving irinotecan hydrochloride with or without alvocidib works in treating patients with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT00991952
- Testing
- alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
- Trial name
- NCT02625623
- Testing
- Avelumab, Irinotecan, Paclitaxel
- Where
- 75 sites in United States, Australia and 8 more
- Volunteers
- 371 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Gastric Cancer
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
This double-blind, placebo-controlled, randomized, multicenter, international, parallel arm study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab, fluoropyrimidine and cisplatin as first-line…
- Trial name
- JACOB (NCT01774786)
- Testing
- 5-Fluorouracil, Capecitabine, Cisplatin
- Where
- 172 sites in United States, Australia and 30 more
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Gastric Cancer
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
This multicenter, randomized, adaptive Phase II/III study will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) compared to standard taxane (docetaxel or paclitaxel) treatment in participants with human epidermal…
- Trial name
- NCT01641939
- Testing
- Taxane, trastuzumab emtansine
- Where
- 148 sites in United States, Argentina and 26 more
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Gastric Adenocarcinoma
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
This is a study of pembrolizumab (MK-3475) as first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT02494583
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Volunteers
- 763 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00601705
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Case Comprehensive Cancer Center
Gastric Cancer
Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer
The primary objective of this study is to demonstrate that addition of cetuximab to 1st-line treatment with capecitabine (Xeloda, X) and cisplatin (P) [XP] chemotherapy regimen has a clinically relevant benefit for subjects with…
- Trial name
- EXPAND (NCT00678535)
- Testing
- Cetuximab, Capecitabine, Cisplatin
- Where
- 130 sites in Argentina, Australia and 23 more
- Volunteers
- 904 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
This phase Ib/II trial studies the side effects and best way to give pembrolizumab with combination chemotherapy and radiation therapy before surgery and to see how well it works in treating adult patients with gastroesophageal…
- Conditions
- Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7
- Trial name
- NCT02730546
- Testing
- Carboplatin, Computed Tomography, Fluorouracil
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- Mayo Clinic
Depression, Fatigue
Programs To Support You During Chemotherapy
This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy.
- Conditions
- Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer
- Trial name
- PRO-YOU (NCT02489422)
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Wake Forest University Health Sciences
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
This pilot clinical trial studies copper Cu 64 (64Cu) tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET)/computed tomography (CT) in studying patients with gastric, or stomach cancer.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach
- Trial name
- NCT01939275
- Testing
- copper Cu 64-DOTA-trastuzumab, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Gastric Cancer
Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer
The purpose of this trial is to evaluate the efficacy of TAS-118 plus Oxaliplatin compared with S-1 plus Cisplatin in overall survival in patients with advanced gastric cancer.
- Trial name
- SOLAR (NCT02322593)
- Testing
- TAS-118 plus Oxaliplatin, S-1 plus Cisplatin
- Where
- 6 sites in Japan, South Korea
- Volunteers
- 711 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Brain Glioblastoma
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
This randomized pilot clinical trial studies health care coach support in reducing acute care use and cost in patients with cancer.
- Conditions
- Acute Myeloid Leukemia, Brain Glioblastoma, Estrogen Receptor Negative, Extensive Stage Small Cell Lung Carcinoma
- Trial name
- NCT03154190
- Testing
- Best Practice, Laboratory Biomarker Analysis, Supportive Care
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- Stanford University
Gastric Cancer, Gastric Adenocarcinoma
A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of rivoceranib plus best supportive care (BSC) compared to placebo plus BSC in participants with advanced or metastatic gastric cancer (GC).
- Trial name
- ANGEL (NCT03042611)
- Testing
- Rivoceranib
- Where
- 95 sites in United States, France and 10 more
- Volunteers
- 460 people
- Sponsor
- Elevar Therapeutics
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
This phase II trial studies the effect of the combination of ramucirumab and trifluridine/tipiracil or paclitaxel in treating patients with previously treated gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT04660760
- Testing
- Paclitaxel, Quality-of-Life Assessment, Ramucirumab
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- Academic and Community Cancer Research United